Skip to content

Cogent Biosciences, Inc. COGT Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Pfizer logo
PfizerPFE
$14.2B+6.8%
Amgen logo
AmgenAMGN
$2.37B+7.0%
Incyte logo
IncyteINCY
$126.59M-27.9%
CG Oncology logo
CG OncologyCGON
$1.45M
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$5.95M+79.2%
Exelixis logo
ExelixisEXEL
$117.33M-2.2%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s other non-current liabilities?
Cogent Biosciences, Inc. (COGT) reported other non-current liabilities of $62K in Q1 2026.
How has Cogent Biosciences, Inc.'s other non-current liabilities changed year-over-year?
Cogent Biosciences, Inc.'s other non-current liabilities increased by 1140.0% year-over-year, from $5K to $62K.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.